A new weight-loss drug, retatrutide, has shown significant results in a clinical trial, with reports of weight loss ranging from up to 28% of body weight to as much as 85 pounds. The drug, developed by Eli Lilly, has been described as a triple agonist and has been compared to weight-loss surgery in terms of its effectiveness. The exact extent of the weight loss achieved with the drug is not consistent across reports, but it is widely characterized as dramatic.